



Article  (Accepted Version)
http://sro.sussex.ac.uk
Pietroboni, Anna M, Carandini, Tiziana, Colombi, Annalisa, Mercurio, Matteo, Ghezzi, Laura, 
Giulietti, Giovanni, Scarioni, Marta, Arighi, Andrea, Fenoglio, Chiara, De Riz, Milena A, Fumagalli, 
Giorgio G, Basilico, Paola, Serpente, Maria, Bozzali, Marco, Scarpini, Elio et al. (2019) Amyloid 
PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation 
with CSF β-amyloid levels and brain volumes. European Journal of Nuclear Medicine and 
Molecular Imaging, 46 (2). pp. 280-287. ISSN 1619-7089 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/80949/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
 1 
 
Amyloid PET as a marker of Normal-Appearing White Matter  
early damage in Multiple Sclerosis:  
correlation with CSF β-Amyloid levels and brain volumes 
 
Anna M. Pietroboni1,2,3*°, Tiziana Carandini1,2,3°, Annalisa Colombi1,2,3, Matteo Mercurio1, Laura 
Ghezzi1,2,3, Giovanni Giulietti4, Marta Scarioni1,2,3, Andrea Arighi1,2,3, Chiara Fenoglio2, Milena A. 
De Riz1,2,3, Giorgio G. Fumagalli1,2,3,5, Paola Basilico1,2,3, Maria Serpente2,  Marco Bozzali4,6, Elio 
Scarpini1,2,3, Daniela Galimberti1,2,3°  and Giorgio Marotta1,2°. 
 
1 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 
2 University of Milan, Italy  
3 Dino Ferrari Center, Milan, Italy  
4 Neuroimaging Laboratory, IRCCS Santa Lucia Foundation, Rome, Italy  
5 Department of Neurosciences, Psychology, Drug Research and Child Health 
(NEUROFARBA), University of Florence, Florence, Italy 
6 Department of Neuroscience, Brighton and Sussex Medical School, University of Sussex, 
Brighton, UK 
 




*Corresponding Author:  
Anna M Pietroboni, Fondazione IRCCS  Ca' Granda Ospedale Policlinico, Via F. Sforza 35, 






Abstract word count: 250 





Purpose: The disease course of multiple sclerosis (MS) is unpredictable and reliable 
prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid 
tracers is a promising tool to evaluate white matter (WM) damage and repair. Our aims 
were to investigate amyloid uptake in damaged (DWM) and normal-appearing WM 
(NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal 
fluid (CSF) β-Amyloid1-42 (Aβ) levels, amyloid tracer uptake and brain volumes.  
Methods: Twelve MS patients were recruited and divided according to their disease 
activity into active and non-active groups. All participants underwent neurological 
examination, neuropsychological testing, lumbar puncture, brain magnetic resonance 
(MRI) imaging, and 18F-florbetapir PET. Aβ levels were determined in CSF samples 
from all patients. MRI and PET images were co-registered and mean standardized 
uptake values (SUV) were calculated for each patient in the NAWM and in the DWM. To 
calculate brain volumes, brain segmentation with statistical parametric mapping 
software was performed. Non-parametric statistical analyses for between-group 
comparisons and regression analyses were conducted. 
Results: We found a lower SUV in DWM compared to NAWM (p<0.001) in all patients. 
A decreased NAWM-SUV in active compared to non-active group was observed 
(p<0.05). Considering only active patients, NAWM volume correlated with NAWM-SUV 
(p=0.01). Interestingly, CSF Aβ concentration was a predictor of both NAWM-SUV 
(r=0.79; p=0.01) and NAWM volume (r=0.81, p=0.01).  
Conclusions: The correlation between CSF Aβ levels and NAWM-SUV suggests that 
the predictive role of β-amyloid may be linked to myelin early damage and may reflect 
the disease activity and the clinical progression.  
Key Words: PET, amyloid tracer, florbetapir, multiple sclerosis, amyloid, white matter 
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INTRODUCTION 
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central 
nervous system (CNS) [1], whose demyelination is the pathological hallmark. MS is 
characterized by inflammation, axonal damage, and neurodegeneration [2]. The factors 
that promote spontaneous remyelination or determine axonal and neuronal loss remain 
poorly understood [3], and currently there are no reliable prognostic biomarkers of disease 
progression. 
Magnetic resonance imaging (MRI) is the most widely used technique for 
identifying the demyelinating lesions, especially in the white matter (WM). However, no 
strong correlation exists between conventional MRI measures, such as T2- and T1-
lesion loads, and risk of disease progression, and no MRI technique is currently specific 
enough to assess myelin damage and repair in vivo [4–6]. 
Positron emission tomography (PET) with amyloid tracers (e.g. Pittsburg 
Compund-B, florbetapir, florbetaben, flutemetamol) was originally developed to image 
amyloid deposition in neurodegenerative disorders and dementia [7], but it has been 
recently repurposed as an imaging marker for quantification of myelin loss and repair in 
MS [5,8–10]. Amyloid tracers bind extensively to WM and its uptake decreases with 
demyelination [8]. The usefulness of amyloid tracers in MS is traditionally considered 
secondary to their non-specific binding to WM, possibly being trapped into β-sheet 
structures of myelin proteins or being highly soluble in the myelin associated lipid bilayer 
[10,11]. Nevertheless, emerging evidence supports a connection between amyloid and 
myelin pathology. Acute WM lesions show a reduced amyloid tracer uptake compared 
with normal appearing WM (NAWM), reflecting a more extensive myelin loss in the 
lesions than in the NAWM [9,10,12,13]. Additionally, in patients with relapsing-remitting 
(RR) MS, an increased uptake within the lesions was found to be associated with a 
more benign clinical evolution [9]. In light of these data, amyloid PET tracers may 
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represent a new tool to monitor MS progression and to provide outcome measures [8]. 
Amyloid PET tracer WM uptake in MS has raised questions about its utility as a 
biomarker of demyelination. Moreover, amyloid-precursor protein (APP) accumulates in 
damaged axons in MS [14,15], suggesting that it may constitute a reliable marker of 
axon demyelination. High APP immunoreactivity has been found in actively 
demyelinating MS lesions but not in chronic ones, indicating a peculiar modification of 
APP metabolism across disease stages [16]. Moreover, β-amyloid (Aβ) might be 
involved in remyelination: the β-site APP-cleaving enzyme 1 (BACE1), the enzyme that 
process APP to generate Aβ, is also involved in the cleavage of neuregulin 1, a protein 
that plays a crucial role in oligodendrocytes differentiation and remyelination. Indeed, 
the genetic deletion of BACE1 during development leads to hypomyelination [17]. 
Several studies have aimed to determine how remyelination and MS are affected by 
APP and the proteins expressed via APP proteolytic processing, and whether amyloid 
PET can provide an in vivo molecular diagnosis of this process, but the question is still 
open.  
Reduced cerebrospinal fluid (CSF) Aβ levels have been reported in MS patients 
[18–22] and have recently been suggested as prognostic biomarker [22,23].  
Given these premises, aims of the current study are: 1) to assess amyloid tracer 
uptake in damaged WM (DWM) and NAWM of MS patients divided according to their 
disease activity; 2) to investigate possible correlations between amyloid tracer uptake 
and CSF Aβ levels, WM brain volumes, and clinical markers of disease progression. 
 
MATERIALS AND METHODS 
Subjects 
Twelve patients with a diagnosis of MS according to the 2010 revised McDonald 
criteria were recruited [24]. Seven patients had RRMS, 3 patients had secondary 
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progressive (SP) subtype, and 2 patients had primary progressive (PP) MS. Then, 
patients were divided according to their disease activity in the last year before the 
recruitment [25]: 8 patients were considered active (active MS) based on clinical 
relapses and/or MRI findings (contrast-enhancing lesions; new or unequivocally 
enlarging T2 lesions), whereas 4 patients were judged stable, with no evidence of acute 
inflammation (non-active MS). The main demographic and clinical characteristics of all 
recruited subjects are summarized in Table 1. 
All patients underwent clinical assessment, neuropsychological evaluation, brain 
MRI, 18F-florbetapir PET, and lumbar puncture (LP). LP was always performed before 
starting any treatment (i.e. corticosteroids). All patients underwent brain MRI for 
diagnostic purposes and 18F-florbetapir PET within a maximum of four weeks after brain 
MRI. For each recruited patient, we assessed the Expanded Disability Status Scale 
(EDSS) score [26] and we calculated the Bayesian Risk Estimate for MS at Onset 
(BREMSO). The BREMSO score has been created in order to assess an individual risk 
score calculated from demographic and clinical variables collected at disease onset. 
The higher the BREMSO score, the higher the risk of future disability [27]. 
The neuropsychological evaluation was assessed on the same day of the 18F-
florbetapir PET using the Italian translation of the Rao Brief Repeatable Battery (BRB-N) 
of Neuropsychological Tests in Multiple Sclerosis [28]. Tests were administered by a 
trained neuropsychologist in a standardized manner, during daytime, in a quiet room, 
and in a fixed order. The administration of the whole battery took about 30 minutes. The 
neuropsychological battery included: selective reminding test (SRT), consistent long 
term retrieval (SRT-CLTR), spatial recall test, oral symbol digit modalities test (SDMT), 
paced auditory serial addition test at 3 (PASAT3) and 2 seconds (PASAT2), selective 
reminding test–delayed recall (SRT-D), and spatial recall test-delayed. 
Neuropsychological tests included in the analyses were adjusted for age, gender, 
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and/or education, according to the Italian validation study [28].  
 
The current study was approved by the Institutional Review Board of the Fondazione Cà 
Granda, IRCCS Ospedale Maggiore Policlinico (Milan, Italy). All MS patients gave their 
written informed consent for this research before entering the study. 
 
CSF collection and Aβ determination 
CSF samples were collected by LP in the L3/L4 or L4/L5 interspace. Following 
LP, CSF samples were centrifuged in 8000 rpm for 10 minutes. The supernatants were 
aliquoted in polypropylene tubes and stored at – 80 °C until use. CSF cell counts, 
glucose, and proteins were determined. Albumin was measured by rate nephelometry. 
Oligoclonal bands (OCB) were evaluated by isoelectrofocusing. CSF Aβ1-42 was 
measured by using a commercially available sandwich enzyme-linked immunosorbent 
assay (ELISA) kit (Fujirebio, Ghent, Belgium).  
 
MRI acquisition 
All patients underwent a MRI examination on Achieva 3T scanner (Philips, The 
Netherlands). The protocol included: 1) a T1-weighted scan (TR 9.90 ms; TE 4.61 ms; 
Flip angle 8°; slices thickness 1 mm; gap 0); 2) Fluid attenuated inversion recovery 
(FLAIR) images (TR 11000 ms; TE 125 ms; Flip angle 90°; slices thickness 1 mm; gap 
0); 3) a T2-weighted scan (TR 2492 ms; TE 78 ms; Flip angle 90°; slices thickness 4 
mm; gap 0).  
 
PET acquisition  
PET scans were obtained with a Biograph Truepoint 64 PET/CT scanner 
(Siemens, Erlangen, Germany). All patients underwent 18F-florbetapir PET scanning at 
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rest after intravenous injection of 370 MBq. Patients were positioned comfortably in a 
quiet room for at least 50 min. Each acquisition included a CT transmission scan of the 
head (55 mAs lasting 10 s) followed by a 20-minute PET list-mode acquisition. PET 
sections were reconstructed with 4 frames of 5 minutes to verify the absence of 
movement of the patients during the acquisition and then with one frame of all 20 
minutes in the form of transaxial images of 168 × 168 pixels of 2 mm, using iterative 3D 
TrueX algorithm with 8 iterations and 14 subsets, with a Gaussian filter with full width at 
half maximum of 4 mm, and corrected for scatter and for attenuation using density 
coefficients derived from the low-dose CT scan of the head obtained with the same 
scanner, with the proprietary software. 
 
Neuroimaging Data Analysis 
The statistical analyses were performed using Statistical Parametric Mapping 
(SPM12, Wellcome Department of Cognitive Neurology, London, UK). Using ImcCalc of 
SPM, Standardized uptake value (SUV) PET maps were derived as SUV= 
AC/(radiotracer dose/BW), where AC represents activity concentration in a given voxel 
[kBq/ml], radiotracer dose is the injected florbetapir dose corrected for residual activity 
in the syringe [MBq], and BW is the body weight [kg]. 
FLAIR- weighted images and SUV-PET images were coregistered to individual 
volumetric T1-weighted images. 
To quantify the macroscopic WM lesion load, lesions were segmented by the 
lesion growth algorithm [29] as implemented in the Lesion Segmentation Tool (LST) 
toolbox version 2.0.15 (www.statistical-modelling.de/lst.html) for SPM. The algorithm 
first segments the T1 images into the main tissue classes. This information is then 
combined with the coregistered FLAIR intensities in order to calculate lesion belief 
maps. By thresholding these maps with a threshold K value of 0.2 (determined by visual 
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inspection of the results of the patients) an initial binary lesion map is obtained which is 
subsequently grown along voxels that appear hyperintense in the FLAIR image and the 
region of interest (ROI) for the DWM was created. For each dataset, the WM lesion load 
was calculated, visually inspected to exclude the presence of macroscopic artifacts and 
used for correlation analyses. 
 Lesions in T1-weighted images were previously filled using the lesion filling tool 
provided by LST toolbox. The lesion-filled T1-series images were segmented according 
to GM, WM and CSF tissue probability maps to generate the normalization deformation 
field into the Montreal Neurological Institute (MNI) space to be applied to the 
coregistered SUV-PET scan.  
Using the WM and GM probability map of segmentation of the individual lesion-
filled T1-images, we extracted the mean SUV of each patient’s total WM by the 
coregistered SUV-PET images. To calculate the mean SUV of NAWM, the volume of 
interest (VOI) representing NAWM was calculated by subtracting the DWM VOI from the 
total WM VOI (Fig. 1). 
GM was evaluated also using the Siemens PET Amyloid Plaque Quantification 
software of the package Molecular Imaging Neurology with syngo.via server, using the 
cortical ROI of anterior cingulated gyrus, orbital part of frontal lobe, superior parietal 
lobule, posterior cingulated gyrus, precuneus, temporal lobe, and of the average of 
these six regions.  
The whole cerebellum was used as the reference region for the standardized 
uptake values relative ratios (SUVR). 
Finally, to obtain brain volumetrics, brain segmentation using SPM12 was 
performed. For each scan, we derived the GM fraction, the total WM fraction, the 
NAWM fraction and the DWM fraction, calculated as the ratio of GM, total WM, NAWM 
and DWM volumes to total intracranial volume (TIV), respectively.  Data were 
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subsequently converted to percentages. 
 
Statistical analysis 
All statistical analyses were performed using SPSS 21.0 for Windows (SPSS 
Inc., Chicago, IL, USA), Graph Pad PRISM 6.0 and SPM12.  
Due to the non-normal distribution of data (as preliminary assessed by Shapiro-
Wilk test), all between-group comparisons were tested by non-parametric inferential 
statistical analyses (Mann-Whitney U test and Wilcoxon test for paired T-test). We used 
a paired t-test for the comparison of the amyloid tracer mean SUV between DWM and 
NAWM. 
All correlation analyses were performed assessing the Pearson correlation 
coefficient. Linear regressions analyses between WM-SUV and NAWM volume as 
dependent variables and CSF Aβ levels as explanatory variable were performed. Each 
regression model was adjusted in order to control for the potential effect of age and 
gender.  
For all analyses the statistical threshold was set to p < 0.05, except for 
correlation between NAWM-SUV and clinical assessment, which was set to p < 0.025 
after Bonferroni correction for multiple comparisons (α = 0.05/2 = 0.025), and for 
correlation between CSF Aβ levels and clinical assessment, which was set to p < 0.016 
after Bonferroni correction for multiple comparisons (α = 0.05/3 = 0.016). 
 
RESULTS 
The main CSF, PET and MRI findings are summarized in Table 2 and in 
Additional Table.  
Concerning the GM tracer uptake, all patients were categorized as amyloid 
negative by quantitative cut-off because their GM-SUVR average was less than 1.10 
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[30]. No correlation between CSF Aβ levels and GM-SUVR average was found (for all 
SUVR see Additional Table). 
 Concerning the WM tracer uptake, DWM-SUV was lower compared to NAWM-
SUV (1.032±0.112 vs. 1.128±0.122; p=0.0005; Fig. 2a) in each subject. Comparing 
patients according to their clinical course (RR vs. SP/PP), no differences in NAWM-SUV 
and DWM-SUV were observed. Conversely, when dividing patients according to their 
disease activity (active group vs. non-active group), we found a reduced NAWM-SUV in 
active group compared to non-active group (1.077±0.119 vs. 1.231±0.023; p=0.028; 
Fig. 2b), whereas no significant differences in DWM-SUV were observed.  
NAWM-SUV correlated with both total WM volume (r=0.73; p=0.006) and NAWM 
volume (r=0.82; p=0.01; Fig. 3), but not with DWM volume (r=-0.45; p>0.05) in all MS 
patients. 
 Focusing on the active group, CSF Aβ levels were lower in patients with WM-
SUV less than 1.05 compared to those with WM-SUV greater than or equal to 1.05 
(698.8±32.57 vs. 1033±226.4; p=0.029; Fig. 4a). Neither DMW-SUV nor NAWM-SUV 
correlated with patients’ age. CSF Aβ levels correlated with NAWM-SUV (r =0.79; 
p=0.017; Fig. 4b). Particularly, the lower the CSF Aβ concentration, the lower the tracer 
uptake in the NAWM. The linear regression analysis showed CSF Aβ levels as a 
predictor of NAWM-SUV (r =0.79; p=0.01). NAWM-SUV correlated with NAWM volume 
(r =0.82; p =0.01; Fig. 4c), but not with DWM volume (r =-0.64; p>0.05). The multiple 
regression analysis showed NAWM volume as the best predictor of NAWM-SUV (r 
=0.87; p=0.007). CSF Aβ levels correlated with NAWM volume (r=0.81; p=0.01; Fig. 
4d), but not with DWM volume (r =-0.36; p>0.05). The multiple regression analysis 
showed CSF Aβ levels as the best predictor of NAWM volume (r=0.81; p=0.007). 
 As regards clinical data, NAWM-SUV showed a trend towards significance in 
active patients as regards the correlation with BREMSO score (r =-0.75; p=0.03), 
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although data did not maintain the statistical significance after Bonferroni correction.  
 CSF Aβ levels correlated with PASAT2 test (r =0.85; p=0.007), whereas the 
correlations with BREMSO score (r=-0.73; p=0.04), EDSS score (r=-0.72; p=0.04) and 
PASAT3 test (r=0.71; p=0.04) lost their significance after Bonferroni correction.  
 
DISCUSSION 
In this study, we report WM-SUV data of amyloid PET in active and non-active 
MS patients with the aim of investigating possible differences between the two groups. 
Furthermore, to the best of our knowledge this is the first attempt to correlate CSF Aβ 
levels and amyloid PET in MS reported so far.  
In line with previous studies [9,10], we find that the amyloid tracer uptake in the 
largest lesion of each patient is reduced compared to their NAWM, confirming the role of 
amyloid PET as a biomarker of myelin loss. 
Moreover, we show that 18F-florbetapir uptake in active patients is lower than in 
non-active patients, suggesting an interesting link between early WM damage and disease 
activity. A previous study described a more marked reduction in the amyloid tracer uptake 
in both DWM and NAWM in patients with progressive MS compared to RR MS patients 
[10].  Authors speculated that such findings may be associated with the reduced 
remyelination present in the progressive forms of the disease [10,31].  
We find that active patients have a lower amyloid tracer uptake compared to non-
active patients, regardless of their disease form, and that the lower uptake is not only in 
the DWM, but also in the NAWM.  
The most interesting finding of our study is that the tracer uptake in the NAWM 
correlates with CSF Aβ levels: the lower the uptake, the lower the CSF Aβ 
concentration. We hypothesize that active patients, i.e. those with lower uptake in both 
DWM and NAWM and with lower CSF Aβ levels, may have a reduced capacity of 
 12 
remyelination and consequently a higher risk of disease progression. To strengthen this 
hypothesis, we also find a lower uptake in the NAWM and lower CSF Aβ levels in those 
patients with a smaller NAWM volume.  
We recently described a relationship between low CSF Aβ levels and worse 
prognosis in MS [22,23]. In line with these findings and hypothesis [22], the correlation 
we describe between amyloid tracer uptake and CSF Aβ concentration suggests that 
amyloid plays a role in the progression of WM damage in MS. Thus, 18F-florbetapir PET 
may represent a marker of early WM damage and a useful prognostic tool. As part of 
this speculation, we had already hypothesized that lower CSF Aβ levels could be 
associated with a decreased ability to remyelinate CNS axons, with an early WM and 
GM damage, resulting in a higher probability of disease progression [22]. Nevertheless, 
the exact role played by Aβ remains to be determined. Further studies are necessary to 
draw a definitive picture.  
There are some limitations when considering our study. First, we acknowledge 
that this represents an exploratory study and that a larger cohort of patients will be 
needed to confirm our findings. The number of patients included was unfortunately 
limited due to the removal of trade of the radiopharmaceutical 18F-florbetapir in Europe 
in January 2018. Second, all patients underwent 18F-florbetapir PET scanning following 
an acquisition protocol validated for AD patients to assure the absence of movements 
during the acquisition. All patients underwent 18F-florbetapir PET scanning following an 
acquisition protocol validated for AD patients to assure the absence of movements 
during the acquisition. Our study was not aimed to optimise the protocol for MS patients, 
but rather to apply the best protocol used to 18F-florbetapir PET acquisition. Because 
all patients, including those with active disease, were very cooperating and none of 
them moved their head during the entire acquisition protocol, static images using for 
measurements were always the 20-minute ones. 
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. 
In conclusion, this study provides evidence on the role of amyloid PET in the 
assessment of MS, particularly in relation to disease activity and early prognosis. 
Moreover, these findings suggest a predictive role of CSF Aβ levels in MS. A replication 
in a larger cohort of patients is required to confirm these preliminary data. 
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Fig. 1: a) T1-weighted MRI; b) coregistrated 18F-florbetapir PET and c) T1-weighted 
MRI/PET fusion images (using the hot iron map); d) T2-weighted FLAIR MRI; e) lesion 
elaboration from Lesion Segmentation Tool (yellow); f) normal appearing white matter 




Fig. 2: a) comparison of the amyloid tracer mean standard uptake value (SUV) in 
damaged white matter (DWM) and normal appearing white matter (NAWM) of all 
patients (p=0.0005). b) comparison of the amyloid tracer mean SUV in the NAWM of 
active and non-active patients (p=0.028). 
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Fig. 3: correlation between the normal appearing white matter (NAWM) amyloid tracer 
mean standard uptake value (SUV) and NAWM volume in all patients. NAWM volume is 
expressed as percentage, calculated as the ratio of NAWM volume to total intracranial 




Fig. 4: a) comparison of CSF levels of β-amyloid in active patients according to their 
normal appearing white matter (NAWM) amyloid tracer mean standard uptake value 
(SUV) (p=0.029). b) correlation between the NAWM amyloid tracer mean SUV and the 
CSF levels of β-amyloid in active patients (r =0.79; p=0.017). c) correlation between the 
NAWM amyloid tracer mean SUV and the NAWM volume in active patients (r =0.82; p 
=0.01). d) correlation between CSF levels of β-amyloid and the NAWM volume in active 
patients (r=0.81; p=0.01). NAWM volume is expressed as percentage, calculated as the 
ratio of NAWM volume to total intracranial volume, per cent. 
 
 
